Health

Basilea Commences Phase 1/2 Study FIDES-03 with Derazantinib

Basilea Commences Phase 1/2 Study FIDES-03 with Derazantinib

Health

Basilea Pharmaceutica has started the phase 1/2 study, FIDES-03, along with the FGFR inhibitor derazantinib. The research is assessing derazantinib in people suffering from advanced gastric cancer along with FGFR genetic abnormality. Derazantinib is reported to be evaluated as monotherapy coupled with extra cancer treatments; for example, Roche’s PD-L1 checkpoint inhibitor, atezolizumab.

The Chief Medical Officer of Basilea, Dr. Marc Engelhardt stated that their development strategy for derazantinib focuses on solidifying the clinical evidence on the difference against other FGFR inhibitors. Derazantinib’s exceptional kinase inhibition profile results from prec

Innovent Biologics announces positive outcomes from ORIENT-32 study

Innovent Biologics announces positive outcomes from ORIENT-32 study

Health

Innovent Biologics Inc., the China-based one leading biopharmaceutical company that develops, manufactures, and distributes top-notch medicines for the treatment of metabolic, oncology, autoimmune diseases, has reportedly announced that its ‘ORIENT-32’ clinical trial has met primary endpoints of PFS (progression-free survival) and OS (overall survival) in an interim study.

For the record, ORIENT-32 is a phase 3 randomized, open-label clinical trial assessing TYVYT® (sintilimab injection) together with BYVASDA® (bevacizumab biosimilar injection, or IBI305) in order to develop a novel first-line treatment for advanced HCC( hepatocellular carcinoma) patien

Algiax Pharmaceuticals enrolls the first patient in CURE study

Algiax Pharmaceuticals enrolls the first patient in CURE study

Health

Clinical-stage biotechnology major, Algiax Pharmaceuticals, has reportedly announced the enrollment of the first patient in the its “CURE” study.

According to Heike Rittner, the Head of Pain Clinic, University Hospital of Wurzburg, the company has witnessed the burden of chronic pain on a daily basis and reportedly opines that these patients are in a desperate need of new treatment alternatives.

She has further stated that the company effectively backs the clinical development of promising treatments, adding that the CURE study and particularly AP-325 is a thrilling example of a development initiative that examines an innova

Scenic Biotech inks genetic modifier collaboration with Genentech

Scenic Biotech inks genetic modifier collaboration with Genentech

Health

Scenic Biotech BV, a pioneer in developing cutting-edge science of genetic modifiers to develop breakthrough therapies, has reportedly inked a multi-year strategic partnership with Genentech Inc. to develop, discover, commercialize new therapeutics can target genetic modifiers.

As per the terms and conditions of the deal, Scenic biotech will use its ‘Cell-Seq’ platform and data warehouse of genetic modifiers to detect drug targets in several therapeutic areas. The partnership enables Genentech to choose numerous targets for further development with a possibility to extend the collaboration.

According to sources familiar with

Viva Biotech, SYNthesis join forces to develop drug services platform

Viva Biotech, SYNthesis join forces to develop drug services platform

Health

Viva Biotech has reportedly signed a Share Purchase Agreement for the purpose of buying 100 per cent equity interest in Hong Kong based SYNthesis Limited for an approximate sum of US$ 80 million. The collaboration will achieve cooperation between SYNthesis and Viva Biotech regarding Viva’s CRO business at the global level. The agreement is of great strategic importance for the conduction of vertical integration and the establishment of an inclusive one-stop drug services platform by Viva Biotech.

Dr. Xianyong Bu, the Managing Director at SYNthesis, has stated that the company is excited to have its team at SYNthesis become part of the Viva family. He has further stat

Atossa reveals positive data from phase 1 study of AT-301 nasal spray

Atossa reveals positive data from phase 1 study of AT-301 nasal spray

Health

A total of over 30 million confirmed COVID-19 cases have been reported across the globe, with the number of deaths nearing one million as of mid-September. With these grim numbers continuing to increase, new treatment approaches are being explored to tackle the pandemic. This is the case of U.S-based Atossa Therapeutics Inc., which is currently conducting a clinical trial for developing ‘AT-301’ nasal sprays in a bid to develop a new treatment option for early-stage COVID-19.

The biopharmaceutical company reportedly announced positive safety outcomes from the second group of healthy individuals in Phase 1 clinical trial using the company’s proprietary dru

LAVA Therapeutics raises $83M in Novo Ventures co-led Series-C funding

LAVA Therapeutics raises $83M in Novo Ventures co-led Series-C funding

Health

Biotech major, LAVA Therapeutics, has reportedly raised a sum of $83 million in a Series C funding initiative for financing the advancement of its platform and pipeline. While the round was co-led by new investors comprising Sanofi Ventures and Novo Ventures, it also included additional investors comprising BB Pureos Bioventures, Redmile Group LLC, and Ysios Capital.

Sources cite that the company’s existing investors including MRL Ventures Fund LLC, Versant, and Gilde Healthcare also recorded significant participation in the funding round.

According to Stephen Hurly, the Chief Executive Officer at LAVA Therapeutics, the company is

FDA approves extended use of Roche’s CINtec PLUS Cytology test

FDA approves extended use of Roche’s CINtec PLUS Cytology test

Health

Roche Holding AG, one of the leading Swiss multinational healthcare companies, has reportedly announced that it has received approval from the US FDA (Food and Drug Admiration) for the extended use of CINtec® PLUS Cytology test. Based on biomarker technology, it is the first triage test for women whose cervical cancer screening outcomes are positive for high-risk types of HPV (Human Papillomavirus).

As per sources familiar with the knowledge of the matter, additional data from this test aids clinical decisions about which patient will benefit most from immediate follow-up. Laboratories can now efficiently use this test to triage positive outcomes from the cobas® HP

Kiadis obtains $9.5 million in funding from ARMI BioFabUSA program

Kiadis obtains $9.5 million in funding from ARMI BioFabUSA program

Health

Clinical stage biopharmaceutical major, Kiadis Pharma N.V., has reportedly received a sum of $9.5 million in financing from the ARMI (Advanced Regenerative Manufacturing Institutes) BioFabUSA initiative. These funds have been reportedly secured in collaboration with the United States Department of Defense for the purpose of funding the company’s K-NK-ID101 program.

Sources cite that Kiadis’ initiative includes research on the activity of K-NK-ID101 and its mode of action in the treatment of COVID-19, comprising the lately declared Dutch research program. The proceeds will be further utilized for supporting an additional company-backed Phase 1/2a clinical trial